Neurobehavioral Manifestations
Signs and symptoms of higher cortical dysfunction caused by organic conditions. These include certain behavioral alterations and impairments of skills involved in the acquisition, processing, and utilization of knowledge or information.
Subtype terms (12)
More specific conditions that are subtypes of Neurobehavioral Manifestations in the MeSH hierarchy.
- Anhedonia
25 drugs (17 approved, 8 experimental)
- Catatonia
2 drugs approved
- Communication Disorders
2 drugs (1 approved, 1 experimental)
- Confusion
10 drugs (7 approved, 3 experimental)
- Consciousness Disorders
22 drugs (17 approved, 5 experimental)
- Intellectual Disability
41 drugs (33 approved, 8 experimental)
- Lethargy
1 drug approved
- Mania
30 drugs (24 approved, 6 experimental)
- Memory Disorders
94 drugs (45 approved, 49 experimental)
- Perceptual Disorders
5 drugs (4 approved, 1 experimental)
- Polydipsia, Psychogenic
1 drug approved
- Psychomotor Disorders
9 drugs (7 approved, 2 experimental)
Drugs by status
Phase 4 trials (5)
Phase 3 trials (2)
Phase 2 trials (4)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (15)
- Novartis
- Central South University
- Case Western Reserve University
- McMaster University
- Stanley Medical Research Institute
- University of Toronto
- Columbia University
- Umea University
- Jiao Tong University
- Chokka Center for Integrative Health
- University of Western Ontario
- The Swedish Research Council
- Lundbeck
- Oskar Foundation
- Jerring Foundation, Sweden
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (8)
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (6)